MacroGenics (NASDAQ:MGNX) is one of the most well-capitalized small-cap biotechnology companies with an impressive list of partners. Their pipeline is diverse and includes bispecifics and immunotherapies, two classes of molecules that have been in the limelight a lot over the last few years.
(click to enlarge)
source: MacroGenics home page
A good chunk of MacroGenics' pipeline is preclinical. Since it typically takes at least 10 years to develop a new drug, a lot is riding on the success of the molecules currently in phase 1 and phase 2: margetuximab, teplizumab, and MGA271. When considering an investment in MGNX, it's worth taking a careful look at these near-term value drivers.
Margetuximab is an anti-HER2 antibody that has been...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|